Unnamed: 0
int64 0
1.41M
| headline
stringlengths 3
513
| url
stringlengths 33
162
| publisher
stringlengths 3
46
| date
timestamp[s] | stock
stringlengths 1
5
|
|---|---|---|---|---|---|
200 | 25 Stocks Moving In Tuesday's Pre-Market Session | https://www.benzinga.com/news/18/05/11712868/25-stocks-moving-in-tuesdays-pre-market-session | Lisa Levin | 2018-05-15T00:00:00 | A |
201 | 10 Stocks Moving In Monday's After-Hours Session | https://www.benzinga.com/news/18/05/11709770/10-stocks-moving-in-mondays-after-hours-session | Brett Hershman | 2018-05-14T00:00:00 | A |
202 | Agilent Technologies Shares Down 6.5% After Hours Following Mixed Q2 Results; Co. Reaffirmed Downbeat Q3 And FY18 Guidance Estimates | https://www.benzinga.com/trading-ideas/movers/18/05/11708729/agilent-technologies-shares-down-6-5-after-hours-following-mixed | Benzinga Newsdesk | 2018-05-14T00:00:00 | A |
203 | Agilent Technologies Reaffirms FY2018 EPS ~$2.65 vs $2.70 Est., Core Sales Growth 5.5% | https://www.benzinga.com/news/18/05/11707843/agilent-technologies-reaffirms-fy2018-eps-2-65-vs-2-70-est-core-sales-growth-5-5 | luke@benzinga.com | 2018-05-14T00:00:00 | A |
204 | Agilent Technologies Sees Q3 EPS $0.61-0.63 vs $0.65 Est; Sees Sales $1.19B-1.21B vs $1.21B Est | https://www.benzinga.com/news/18/05/11707834/agilent-technologies-sees-q3-eps-0-61-0-63-vs-0-65-est-sees-sales-1-19b-1-21b-vs | luke@benzinga.com | 2018-05-14T00:00:00 | A |
205 | Agilent Technologies Q2 EPS $0.65 Beats $0.64 Estimate, Sales $1.206B Miss $1.21B Estimate | https://www.benzinga.com/news/earnings/18/05/11707818/agilent-technologies-q2-eps-0-65-beats-0-64-estimate-sales-1-206b-miss- | Benzinga Newsdesk | 2018-05-14T00:00:00 | A |
206 | The Week Ahead: Coindesk Conference, Walmart And Retailers Close Out Earnings Season | https://www.benzinga.com/markets/cryptocurrency/18/05/11703630/the-week-ahead-coindesk-conference-walmart-and-retailers-close | Taylor Cox | 2018-05-14T00:00:00 | A |
207 | 7 Stocks To Watch For May 14, 2018 | https://www.benzinga.com/news/earnings/18/05/11701862/7-stocks-to-watch-for-may-14-2018 | Lisa Levin | 2018-05-14T00:00:00 | A |
208 | Earnings Scheduled For May 14, 2018 | https://www.benzinga.com/news/earnings/18/05/11701850/earnings-scheduled-for-may-14-2018 | Lisa Levin | 2018-05-14T00:00:00 | A |
209 | Agilent Reports Purchase Of Genohm, No Terms Disclosed | https://www.benzinga.com/news/m-a/18/05/11631787/agilent-reports-purchase-of-genohm-no-terms-disclosed | Paul Quintaro | 2018-05-02T00:00:00 | A |
210 | Agilent Technologies Files Second Civil Action Against Changzhou Pannatek to 'Protect Intellectual Property' | https://www.benzinga.com/news/18/04/11537039/agilent-technologies-files-second-civil-action-against-changzhou-pannatek-to-pro | Hal Lindon | 2018-04-18T00:00:00 | A |
211 | Morgan Stanley Maintains Overweight on Agilent Technologies, Lowers Price Target to $91.00 | https://www.benzinga.com/news/18/04/11501504/morgan-stanley-maintains-overweight-on-agilent-technologies-lowers-price-target- | Vick Meyer | 2018-04-11T00:00:00 | A |
212 | UPDATE: Alnylam, Agilent Deal Has Initial Term Of 5 Years, With Automatic Renewal Terms OF 2 Years Absent Earlier Termination, No Further Terms Disclosed | https://www.benzinga.com/news/18/04/11464543/update-alnylam-agilent-deal-has-initial-term-of-5-years-with-automatic-renewal-t | Paul Quintaro | 2018-04-03T00:00:00 | A |
213 | Alnylam Pharma 8-K Shows Co. Entered Manufacturing Services Deal With Agilent For Providing Of Commercial Supply Of Patisiran | https://www.benzinga.com/news/18/04/11464538/alnylam-pharma-8-k-shows-co-entered-manufacturing-services-deal-with-agilent-for | Paul Quintaro | 2018-04-03T00:00:00 | A |
214 | Agilent Technologies Signs Agreement To Acquire Lasergen For $105M | https://www.benzinga.com/news/m-a/18/04/11464262/agilent-technologies-signs-agreement-to-acquire-lasergen-for-105m | Eddie Staley | 2018-04-03T00:00:00 | A |
215 | Agilent Technologies to Acquire Advanced Analytical Technologies for $250M in Cash | https://www.benzinga.com/news/18/03/11324655/agilent-technologies-to-acquire-advanced-analytical-technologies-for-250m-in-cas | Charles Gross | 2018-03-07T00:00:00 | A |
216 | Bank Of America Out Positive On Agilent, Raises Price Target From $80 To $83 As Frim Says Core Business Continues To Do Well, Led By C&E Strength And Pharma; Remains A Focus Stock For Bank of America | https://www.benzinga.com/analyst-ratings/analyst-color/18/02/11209782/bank-of-america-out-positive-on-agilent-raises-price-ta | Eddie Staley | 2018-02-15T00:00:00 | A |
217 | JP Morgan Maintains Overweight on Agilent Technologies Inc, Raises price target to $80.00 | https://www.benzinga.com/news/18/02/11209413/jp-morgan-maintains-overweight-on-agilent-technologies-inc-raises-price-target-t | Vick Meyer | 2018-02-15T00:00:00 | A |
218 | Agilent Sees Q2 Adj. EPS $0.61-$0.63 vs $0.64 Est., Sales $1.2B-$1.22B vs $1.17B Est.; FY18 Adj. EPS $2.62-$2.68 vs $2.59 Est., Sales $4.885B-$4.905B vs $5.04B Est. | https://www.benzinga.com/news/guidance/18/02/11204101/agilent-sees-q2-adj-eps-0-61-0-63-vs-0-64-est-sales-1-2b-1-22b-vs-1-17b | Hal Lindon | 2018-02-14T00:00:00 | A |
219 | Agilent Reports Q1 Adj. EPS $0.66 vs $0.58 Est., Sales $1.21B vs $1.16B Est. | https://www.benzinga.com/news/earnings/18/02/11204092/agilent-reports-q1-adj-eps-0-66-vs-0-58-est-sales-1-21b-vs-1-16b-est | Hal Lindon | 2018-02-14T00:00:00 | A |
220 | Earnings Scheduled For February 14, 2018 | https://www.benzinga.com/news/earnings/18/02/11194554/earnings-scheduled-for-february-14-2018 | Lisa Levin | 2018-02-14T00:00:00 | A |
221 | Phillips 66 Says it Has Agreed to Repurchase 35M Shares of Phillips 66 Common Stock from Wholly-owned Subsidiary of Berkshire Hathaway | https://www.benzinga.com/news/18/02/11193708/phillips-66-says-it-has-agreed-to-repurchase-35m-shares-of-phillips-66-common-st | Charles Gross | 2018-02-13T00:00:00 | A |
222 | Agilent Reports Scientific Partnership with the University of Southern California | https://www.benzinga.com/news/18/01/11094506/agilent-reports-scientific-partnership-with-the-university-of-southern-californi | Eddie Staley | 2018-01-29T00:00:00 | A |
223 | The 10 Most Expensive Stocks In The S&P 500 | https://www.benzinga.com/trading-ideas/long-ideas/18/01/11067296/the-10-most-expensive-stocks-in-the-s-p-500 | Matt Hogan - Finbox.io | 2018-01-23T00:00:00 | A |
224 | JP Morgan Healthcare Conference Continues Today, Presenters Include: Bluebird Bio, Agilent, Insulet, Cigna, DexCom, Eli Lilly, LifePoint, Acadia, Alkermes, Juno Therapeutics | https://www.benzinga.com/general/biotech/18/01/11007193/jp-morgan-healthcare-conference-continues-today-presenters-include-bl | Hal Lindon | 2018-01-09T00:00:00 | A |
225 | Agilent Reports Purchase Of Luxcel Biosciences, No Terms Disclosed | https://www.benzinga.com/news/m-a/18/01/11006799/agilent-reports-purchase-of-luxcel-biosciences-no-terms-disclosed | Paul Quintaro | 2018-01-09T00:00:00 | A |
226 | Evercore ISI Group Initiates Coverage On Agilent Technologies with Outperform Rating, Announces $75.00 Price Target | https://www.benzinga.com/news/18/01/10986842/evercore-isi-group-initiates-coverage-on-agilent-technologies-with-outperform-ra | Eddie Staley | 2018-01-04T00:00:00 | A |
227 | Goldman Sachs Healthcare CEOs Unscripted Conference Taking Place Today; Presenters Include Agilent, Bluebird Bio, Boston Scientific, Alexion, Eli Lilly, and Alnylam | https://www.benzinga.com/general/biotech/18/01/10985998/goldman-sachs-healthcare-ceos-unscripted-conference-taking-place-toda | Hal Lindon | 2018-01-04T00:00:00 | A |
228 | Aquinox Pharmaceuticals Announces FDA Panel Voted 15 to 0 That Patients With Interstitial Cystitis and Patients With Bladder Pain Syndrome Should Be Combined in Clinical Trials | https://www.benzinga.com/news/17/12/10889742/aquinox-pharmaceuticals-announces-fda-panel-voted-15-to-0-that-patients-with-int | Charles Gross | 2017-12-08T00:00:00 | A |
229 | Deutsche Bank Says Agilent Can Be The Next 'Compounder' In The Life Science Tools & Diagnostics Space Based On Product Cycles, Margin Expansion Opportunities, and Balanced End Market Exposures | https://www.benzinga.com/analyst-ratings/analyst-color/17/11/10818386/deutsche-bank-says-agilent-can-be-the-next-compounder-i | Eddie Staley | 2017-11-21T00:00:00 | A |
230 | 33 Stocks Moving In Tuesday's Pre-Market Session | https://www.benzinga.com/news/17/11/10816699/33-stocks-moving-in-tuesdays-pre-market-session | Lisa Levin | 2017-11-21T00:00:00 | A |
231 | 14 Stocks To Watch For November 21, 2017 | https://www.benzinga.com/news/earnings/17/11/10815780/14-stocks-to-watch-for-november-21-2017 | Lisa Levin | 2017-11-21T00:00:00 | A |
232 | 7 Stock's Moving In Monday's After-Hours Session | https://www.benzinga.com/news/17/11/10814397/7-stocks-moving-in-mondays-after-hours-session | Brett Hershman | 2017-11-20T00:00:00 | A |
233 | Agilent Sees Q1 Adj. EPS $0.55-$0.57 vs $0.60 Est., Sales $1.145B-$1.165B vs $1.15B Est. | https://www.benzinga.com/news/guidance/17/11/10813488/agilent-sees-q1-adj-eps-0-55-0-57-vs-0-60-est-sales-1-145b-1-165b-vs-1- | Paul Quintaro | 2017-11-20T00:00:00 | A |
234 | Agilent Sees FY18 Adj. EPS $2.50-$2.56 vs $2.59 Est., Sales $4.72B-$4.74B vs $4.73B Est. | https://www.benzinga.com/news/guidance/17/11/10813481/agilent-sees-fy18-adj-eps-2-50-2-56-vs-2-59-est-sales-4-72b-4-74b-vs-4- | Paul Quintaro | 2017-11-20T00:00:00 | A |
235 | Agilent Reports Q4 Adj. EPS $0.67 vs $0.62 Est., Sales $1.19B vs $1.17B Est. | https://www.benzinga.com/news/earnings/17/11/10813466/agilent-reports-q4-adj-eps-0-67-vs-0-62-est-sales-1-19b-vs-1-17b-est | Paul Quintaro | 2017-11-20T00:00:00 | A |
236 | 7 Stocks To Watch For November 20, 2017 | https://www.benzinga.com/news/earnings/17/11/10809301/7-stocks-to-watch-for-november-20-2017 | Lisa Levin | 2017-11-20T00:00:00 | A |
237 | Earnings Scheduled For November 20, 2017 | https://www.benzinga.com/news/earnings/17/11/10809280/earnings-scheduled-for-november-20-2017 | Lisa Levin | 2017-11-20T00:00:00 | A |
238 | Agilent Raises Qtr. Dividend From $0.13/Share To $0.149/Share | https://www.benzinga.com/trading-ideas/dividends/17/11/10793268/agilent-raises-qtr-dividend-from-0-13share-to-0-149share | Hal Lindon | 2017-11-15T00:00:00 | A |
239 | Morgan Stanley Maintains Overweight on Agilent Technologies, Raises Price Target to $88.00 | https://www.benzinga.com/news/17/11/10779107/morgan-stanley-maintains-overweight-on-agilent-technologies-raises-price-target- | vivek.proactive@gmail.com | 2017-11-14T00:00:00 | A |
240 | Agilent Technologies Receives FDA Approval For Use Of Dako PD-L1 For Treatment With Merck's KEYTRUDA In Gastric or Gastroesophageal Junction Cancer | https://www.benzinga.com/general/biotech/17/09/10092187/agilent-technologies-receives-fda-approval-for-use-of-dako-pd-l1-for- | Hal Lindon | 2017-09-22T00:00:00 | A |
241 | Agilent Reports Dako PD-L1 IHC 28-8 PharmDx Approved For 2 New Indications: Urothelial Carcinoma, Squamous Cell Carcinoma Of Head And Neck | https://www.benzinga.com/news/17/09/10073983/agilent-reports-dako-pd-l1-ihc-28-8-pharmdx-approved-for-2-new-indications-uroth | Paul Quintaro | 2017-09-19T00:00:00 | A |
242 | Agilent Reports FDA Approval Of GenetiSure Dx Postnatal Assay | https://www.benzinga.com/news/fda/17/09/10051823/agilent-reports-fda-approval-of-genetisure-dx-postnatal-assay | Paul Quintaro | 2017-09-13T00:00:00 | A |
243 | Agilent Files Civil Lawsuit against Shanghai Echrom Electronic Technology Co. | https://www.benzinga.com/news/17/08/9964556/agilent-files-civil-lawsuit-against-shanghai-echrom-electronic-technology-co | Charles Gross | 2017-08-23T00:00:00 | A |
244 | 12 Biggest Mid-Day Gainers For Wednesday | https://www.benzinga.com/news/17/08/9940208/12-biggest-mid-day-gainers-for-wednesday | Lisa Levin | 2017-08-16T00:00:00 | A |
245 | 3 Things Deutsche Bank Likes About Agilent's Q3, And One Thing To Be Cautious Of | https://www.benzinga.com/analyst-ratings/analyst-color/17/08/9939406/3-things-deutsche-bank-likes-about-agilents-q3-and-one-t | Jayson Derrick | 2017-08-16T00:00:00 | A |
246 | 5 Things That Stood Out In Another Beat And Raise Quarter From Agilent | https://www.benzinga.com/analyst-ratings/analyst-color/17/08/9938927/5-things-that-stood-out-in-another-beat-and-raise-quarte | Jayson Derrick | 2017-08-16T00:00:00 | A |
247 | 20 Stocks Moving In Wednesday's Pre-Market Session | https://www.benzinga.com/news/17/08/9938514/20-stocks-moving-in-wednesdays-pre-market-session | Lisa Levin | 2017-08-16T00:00:00 | A |
248 | A Peek Into The Markets: U.S. Stock Futures Rise; All Eyes On Fed Minutes | https://www.benzinga.com/news/17/08/9938161/a-peek-into-the-markets-u-s-stock-futures-rise-all-eyes-on-fed-minutes | Lisa Levin | 2017-08-16T00:00:00 | A |
249 | 8 Stocks To Watch For August 16, 2017 | https://www.benzinga.com/news/earnings/17/08/9937588/8-stocks-to-watch-for-august-16-2017 | Lisa Levin | 2017-08-16T00:00:00 | A |
250 | Agilent Sees Q4 Adj. EPS $0.60-$0.62 vs $0.60 Est., Sales $1.15B-$1.17B vs $1.15B Est.; FY17 Adj. EPS $2.29-$2.31 vs $2.23 Est., Sales $4.435B-$4.455B vs $4.41B Est. | https://www.benzinga.com/news/guidance/17/08/9935739/agilent-sees-q4-adj-eps-0-60-0-62-vs-0-60-est-sales-1-15b-1-17b-vs-1-15b | Hal Lindon | 2017-08-15T00:00:00 | A |
251 | Agilent Technologies Reports Q3 Adj. EPS $0.59 vs $0.52 Est., Sales $1.11B vs $1.09B Est. | https://www.benzinga.com/news/earnings/17/08/9935708/agilent-technologies-reports-q3-adj-eps-0-59-vs-0-52-est-sales-1-11b-vs- | Hal Lindon | 2017-08-15T00:00:00 | A |
252 | 10 Stocks To Watch For August 15, 2017 | https://www.benzinga.com/news/earnings/17/08/9931180/10-stocks-to-watch-for-august-15-2017 | Lisa Levin | 2017-08-15T00:00:00 | A |
253 | Earnings Scheduled For August 15, 2017 | https://www.benzinga.com/news/earnings/17/08/9931140/earnings-scheduled-for-august-15-2017 | Lisa Levin | 2017-08-15T00:00:00 | A |
254 | Agilent Acquires Powerful Next Gen Sequencing IP Portfolio, No Terms Disclosed | https://www.benzinga.com/news/m-a/17/07/9813123/agilent-acquires-powerful-next-gen-sequencing-ip-portfolio-no-terms-disclosed | Hal Lindon | 2017-07-24T00:00:00 | A |
255 | Wells Fargo Upgrades Agilent Technologies to Outperform | https://www.benzinga.com/news/17/07/9772195/wells-fargo-upgrades-agilent-technologies-to-outperform | Paul Quintaro | 2017-07-13T00:00:00 | A |
256 | Agilent Reports Purchase Of Cobalt Light Systems For £40M In Cash | https://www.benzinga.com/news/m-a/17/07/9751414/agilent-reports-purchase-of-cobalt-light-systems-for-40m-in-cash | Paul Quintaro | 2017-07-07T00:00:00 | A |
257 | Unisys ClearPath Software Selected by Malaysia's ANGKASA | https://www.benzinga.com/17/06/9664395/unisys-clearpath-software-selected-by-malaysias-angkasa | Zacks | 2017-06-28T00:00:00 | A |
258 | Why Agilent Technologies (A) Stock Might be a Great Pick | https://www.benzinga.com/17/06/9646903/why-agilent-technologies-a-stock-might-be-a-great-pick | Zacks | 2017-06-23T00:00:00 | A |
259 | Why Agilent Technologies (A) Stock Might be a Great Pick | https://www.benzinga.com/17/06/9646904/why-agilent-technologies-a-stock-might-be-a-great-pick | Zacks | 2017-06-23T00:00:00 | A |
260 | All Mixed Up | https://www.benzinga.com/17/06/9622814/all-mixed-up | Zacks | 2017-06-19T00:00:00 | A |
261 | Goldman Sachs Global Healthcare Conference Continues Today, Presenters Include: Agilent, Sage Therapeutics, and GW Pharmaceuticals | https://www.benzinga.com/general/biotech/17/06/9606321/goldman-sachs-global-healthcare-conference-continues-today-presenters- | Hal Lindon | 2017-06-14T00:00:00 | A |
262 | Unisys Launches FamilyNow for Aiding Social Service Agencies | https://www.benzinga.com/17/06/9583163/unisys-launches-familynow-for-aiding-social-service-agencies | Zacks | 2017-06-08T00:00:00 | A |
263 | Jefferies Health Care Conference Begins Today, Presenters Include: Agilent Technologies, Civitas Solutions, Aeri Pharmaceuticals, Alkermes, Alnylam Pharmaceuticals, Heron Therapeutics | https://www.benzinga.com/news/events/17/06/9569848/jefferies-health-care-conference-begins-today-presenters-include-agilent-t | Hal Lindon | 2017-06-06T00:00:00 | A |
264 | Agilent Reports Deal with Agendia for Molecular Cancer Diagnostics | https://www.benzinga.com/news/17/06/9556845/agilent-reports-deal-with-agendia-for-molecular-cancer-diagnostics | Paul Quintaro | 2017-06-02T00:00:00 | A |
265 | Agilent Spikes to High of $60.40 on Volume | https://www.benzinga.com/movers/17/05/9535499/agilent-spikes-to-high-of-60-40-on-volume | Charles Gross | 2017-05-30T00:00:00 | A |
266 | 15 Biggest Mid-Day Gainers For Tuesday | https://www.benzinga.com/news/17/05/9506817/15-biggest-mid-day-gainers-for-tuesday | Lisa Levin | 2017-05-23T00:00:00 | A |
267 | Agilent Technologies Sharply Higher After Q2 Beat | https://www.benzinga.com/trading-ideas/technicals/17/05/9506382/agilent-technologies-sharply-higher-after-q2-beat | Joel Elconin | 2017-05-23T00:00:00 | A |
268 | 5 Biggest Price Target Changes For Tuesday | https://www.benzinga.com/analyst-ratings/price-target/17/05/9505512/5-biggest-price-target-changes-for-tuesday | Lisa Levin | 2017-05-23T00:00:00 | A |
269 | 20 Stocks Moving In Tuesday's Pre-Market Session | https://www.benzinga.com/news/17/05/9504474/20-stocks-moving-in-tuesdays-pre-market-session | Lisa Levin | 2017-05-23T00:00:00 | A |
270 | A Peek Into The Markets: U.S. Stock Futures Gain Ahead Of Economic Reports | https://www.benzinga.com/news/earnings/17/05/9504123/a-peek-into-the-markets-u-s-stock-futures-gain-ahead-of-economic-reports | Lisa Levin | 2017-05-23T00:00:00 | A |
271 | 8 Stocks To Watch For May 23, 2017 | https://www.benzinga.com/news/earnings/17/05/9503603/8-stocks-to-watch-for-may-23-2017 | Lisa Levin | 2017-05-23T00:00:00 | A |
272 | UPDATE: Agilent Raises FY17 Adj. EPS Outlook to $2.15-$2.21 vs $2.16 Est., Sales to $4.36B-$4.38B vs $4.35B Est. | https://www.benzinga.com/news/guidance/17/05/9501022/update-agilent-raises-fy17-adj-eps-outlook-to-2-15-2-21-vs-2-16-est-sale | Paul Quintaro | 2017-05-22T00:00:00 | A |
273 | Agilent Sees Q3 Adj. EPS $0.49-$0.51 vs $0.53 Est., Sales $1.06B-$1.08B vs $1.08B Est. | https://www.benzinga.com/news/17/05/9501004/agilent-sees-q3-adj-eps-0-49-0-51-vs-0-53-est-sales-1-06b-1-08b-vs-1-08b-est | Paul Quintaro | 2017-05-22T00:00:00 | A |
274 | Agilent Raises FY Outlook | https://www.benzinga.com/news/guidance/17/05/9500994/agilent-raises-fy-outlook | Paul Quintaro | 2017-05-22T00:00:00 | A |
275 | Agilent Reports Q2 Adj. EPS $0.58 vs $0.48 Est., Sales $1.1B vs $1.05B Est. | https://www.benzinga.com/news/earnings/17/05/9500986/agilent-reports-q2-adj-eps-0-58-vs-0-48-est-sales-1-1b-vs-1-05b-est | Paul Quintaro | 2017-05-22T00:00:00 | A |
276 | 5 Stocks To Watch For May 22, 2017 | https://www.benzinga.com/news/earnings/17/05/9496980/5-stocks-to-watch-for-may-22-2017 | Lisa Levin | 2017-05-22T00:00:00 | A |
277 | Earnings Scheduled For May 22, 2017 | https://www.benzinga.com/news/earnings/17/05/9496934/earnings-scheduled-for-may-22-2017 | Lisa Levin | 2017-05-22T00:00:00 | A |
278 | 7 Biggest Price Target Changes For Friday | https://www.benzinga.com/analyst-ratings/price-target/17/03/9242558/7-biggest-price-target-changes-for-friday | Lisa Levin | 2017-03-31T00:00:00 | A |
279 | Agilent Names Koh Boon Hwee Chair | https://www.benzinga.com/news/management/17/03/9177143/agilent-names-koh-boon-hwee-chair | Paul Quintaro | 2017-03-15T00:00:00 | A |
280 | 18 Biggest Mid-Day Gainers For Wednesday | https://www.benzinga.com/news/17/03/9175725/18-biggest-mid-day-gainers-for-wednesday | Lisa Levin | 2017-03-15T00:00:00 | A |
281 | Benzinga's Top Upgrades, Downgrades For March 15, 2017 | https://www.benzinga.com/analyst-ratings/upgrades/17/03/9174420/benzingas-top-upgrades-downgrades-for-march-15-2017 | Lisa Levin | 2017-03-15T00:00:00 | A |
282 | Morgan Stanley Upgrades Agilent Technologies To Overweight | https://www.benzinga.com/news/17/03/9173381/morgan-stanley-upgrades-agilent-technologies-to-overweight | Paul Quintaro | 2017-03-15T00:00:00 | A |
283 | The Technician's Playbook: 11 Sector Pair Trades | https://www.benzinga.com/analyst-ratings/analyst-color/17/03/9163986/the-technicians-playbook-11-sector-pair-trades | Shanthi Rexaline | 2017-03-13T00:00:00 | A |
284 | Cowen Annual Healthcare Conference Concludes Today; Presenters Include Agilent Tech, Incyte, GW Pharma, Teva Pharma, NantKwest, Seattle Genetics, And Celgene | https://www.benzinga.com/news/events/17/03/9145499/cowen-annual-healthcare-conference-concludes-today-presenters-include-agil | Hal Lindon | 2017-03-08T00:00:00 | A |
285 | 5 Biggest Price Target Changes For Wednesday | https://www.benzinga.com/analyst-ratings/price-target/17/02/9053624/5-biggest-price-target-changes-for-wednesday | Lisa Levin | 2017-02-15T00:00:00 | A |
286 | Agilent Raises FY17 Outlook | https://www.benzinga.com/news/guidance/17/02/9048063/agilent-raises-fy17-outlook | Paul Quintaro | 2017-02-14T00:00:00 | A |
287 | Agilent Reports Q1 Adj. EPS $0.53 vs $0.49 Est., Sales $1.07B vs $1.05B Est. | https://www.benzinga.com/news/earnings/17/02/9048061/agilent-reports-q1-adj-eps-0-53-vs-0-49-est-sales-1-07b-vs-1-05b-est | Paul Quintaro | 2017-02-14T00:00:00 | A |
288 | Earnings Scheduled For February 14, 2017 | https://www.benzinga.com/news/earnings/17/02/9039838/earnings-scheduled-for-february-14-2017 | Lisa Levin | 2017-02-14T00:00:00 | A |
289 | Deutsche Bank Optimistic On Fundamentals In Life Science Tools/Diagnostics Sector | https://www.benzinga.com/analyst-ratings/analyst-color/17/01/8917960/deutsche-bank-optimistic-on-fundamentals-in-life-science | Manikandan Raman | 2017-01-18T00:00:00 | A |
290 | Hearing Thermo Fisher In Talks To Buy Agilent | https://www.benzinga.com/news/17/01/8894810/hearing-thermo-fisher-in-talks-to-buy-agilent | Paul Quintaro | 2017-01-11T00:00:00 | A |
291 | 7 Biggest Price Target Changes For Wednesday | https://www.benzinga.com/analyst-ratings/price-target/17/01/8863908/7-biggest-price-target-changes-for-wednesday | Lisa Levin | 2017-01-04T00:00:00 | A |
292 | Benzinga's Top Upgrades, Downgrades For January 4, 2017 | https://www.benzinga.com/analyst-ratings/upgrades/17/01/8863789/benzingas-top-upgrades-downgrades-for-january-4-2017 | Lisa Levin | 2017-01-04T00:00:00 | A |
293 | Barclays Upgrades Agilent Technologies to Overweight, Raises Target to $51.00 | https://www.benzinga.com/news/17/01/8863226/barclays-upgrades-agilent-technologies-to-overweight-raises-target-to-51-00 | Paul Quintaro | 2017-01-04T00:00:00 | A |
294 | Agilent to Buy Multiplicom for â¬68M in Cash | https://www.benzinga.com/news/m-a/16/12/8827997/agilent-reports-purchase-of-multiplicom-for-58m-in-cash | Paul Quintaro | 2016-12-20T00:00:00 | A |
295 | Pressure Biosciences CEO On Its Beaten Down Stock: 'We Can Now Begin To Focus On The Area That Is Most Important' | https://www.benzinga.com/general/biotech/16/12/8772864/pressure-biosciences-ceo-on-its-beaten-down-stock-we-can-now-begin-to- | Javier Hasse | 2016-12-06T00:00:00 | A |
296 | The Market In 5 Minutes: DryShips, Trump And Target | https://www.benzinga.com/news/16/11/8706577/the-market-in-5-minutes-dryships-trump-and-target | Benzinga News Desk | 2016-11-16T00:00:00 | A |
297 | A Peek Into The Markets: U.S. Stock Futures Decline Ahead Of Economic Data | https://www.benzinga.com/news/earnings/16/11/8706678/a-peek-into-the-markets-u-s-stock-futures-decline-ahead-of-economic-data | Lisa Levin | 2016-11-16T00:00:00 | A |
298 | Keep an Eye on These 8 Stocks for November 16, 2016 | https://www.benzinga.com/news/earnings/16/11/8706188/keep-an-eye-on-these-8-stocks-for-november-16-2016 | Lisa Levin | 2016-11-16T00:00:00 | A |
299 | Agilent Technologies Sees FY17 Rev. $4.35B-$4.37B vs. Est. $4.35B, EPS $2.10-$2.16 vs. Est. $2.19; Q4 Rev. $1.04-$1.04B vs. Est. $1.08B, EPS $0.48-$0.50 vs. Est. $0.53 | https://www.benzinga.com/news/16/11/8704114/agilent-technologies-sees-fy17-rev-4-35b-4-37b-vs-est-4-35b-eps-2-10-2-16-vs-est- | Paul Quintaro | 2016-11-15T00:00:00 | A |